Compare AFG & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AFG | EXEL |
|---|---|---|
| Founded | 1872 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 11.1B |
| IPO Year | N/A | 2000 |
| Metric | AFG | EXEL |
|---|---|---|
| Price | $137.19 | $41.40 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 24 |
| Target Price | ★ $131.00 | $45.18 |
| AVG Volume (30 Days) | 394.0K | ★ 2.6M |
| Earning Date | 02-03-2026 | 11-04-2025 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | N/A | ★ 53.55 |
| EPS | ★ 9.52 | 2.38 |
| Revenue | ★ $8,011,000,000.00 | $2,288,218,000.00 |
| Revenue This Year | N/A | $9.84 |
| Revenue Next Year | $4.91 | $11.92 |
| P/E Ratio | ★ $14.41 | $17.20 |
| Revenue Growth | 1.20 | ★ 9.93 |
| 52 Week Low | $114.73 | $31.90 |
| 52 Week High | $150.02 | $49.62 |
| Indicator | AFG | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 54.44 | 46.23 |
| Support Level | $132.18 | $40.66 |
| Resistance Level | $134.56 | $44.79 |
| Average True Range (ATR) | 2.45 | 1.15 |
| MACD | 0.23 | -0.43 |
| Stochastic Oscillator | 82.17 | 15.53 |
American Financial Group Inc is a holding company that is engaged in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. The Company operates through two segments: Property & Casualty Insurance and Other. The Property & Casualty segment includes Property & Transportation, covering buses, trucks, marine, agriculture, and commercial property; Specialty Casualty, offering excess & surplus, liability, and professional insurance; and Specialty Financial, providing risk management for lending and leasing institutions, fidelity and surety products, and trade credit insurance. The company's insurance operations are conducted through the Great American Insurance Group.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.